Boston, Mass. — Dennis Jones, PhD, assistant professor of pathology & laboratory medicine at Boston University Chobanian & Avedisian School of Medicine, has been awarded a two-year, $330,000 grant from the Department of Defense for his research, “Enhancing Lymphatic Function with Transplanted Muscle Cells after Bacterial Infection.” Lymphedema is a...
Latest News
BOSTON, Mass. — David T. Felson, MD, MPH and Tuhina Neogi, MD, PhD professors of medicine at Boston University Chobanian & Avedisian School of Medicine and of epidemiology at the School of Public Health, have been awarded a U19 grant from the NIH’s National Institute on Aging. The five-year, $46...
Boston, Mass. – Identifying genetic variants and the role they play in predisposing people to Alzheimer’s disease can help researchers better understand how to treat the neurodegenerative condition for which there is currently no cure. A new study led by Boston University School of Public Health (BUSPH) and UTHealth Houston...
Boston, Mass. – The largest study ever of 77 deceased male ice hockey players by the Boston University CTE Center found that the odds of having chronic traumatic encephalopathy (CTE) increased by 34% each year played, and 18 of 19 National Hockey League players had CTE. CTE is a neurodegenerative...
WALTHAM, Mass. — BostonGene, a leading provider of AI-based molecular and immune profiling solutions provider, today announces a collaboration with Prisma Health aimed at advancing the understanding of rare tumors by characterizing the tumor microenvironment (TME), mutational landscape and host immune profiles of patients treated with immune checkpoint inhibitors. In...
LEXINGTON, Mass. — Agenus Inc., a leader in developing immunological cancer treatments, today announced results from the NEST-1 study, an investigator-sponsored trial (IST) evaluating the combination of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer (CRC), both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High...
LMU researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer. Munich, Germany — Colorectal cancer (bowel cancer) is the third most common form of cancer worldwide, with around 1.9 million newly diagnosed cases and 900,000 deaths every year. Therefore, preventive substances represent an urgent clinical need....
GRAND RAPIDS, Mich. – Six-year-old Jacob Geer takes 12 pills every day to control his seizures, is fed by a tube and regularly visits a variety of doctors. He will be lucky to celebrate his 12th birthday. One year ago, Jacob was diagnosed with Batten disease, a genetic disorder of...
BOSTON, Mass. — BPGbio Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced the completion of enrollment in its Phase IIb trial of BPM31510-IV, in combination with Vitamin K1, for patients with newly diagnosed glioblastoma multiforme (GBM). Following a Phase 1 study in GBM, demonstrating acceptable tolerability and safety,...
BOSTON, Mass. — BPGbio, Inc. a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today will announce new data from a phase 2a clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held January...